Eli Lilly and Company
LLY · NYSE
$1,138.28+$227.7325.01%
$1,136.16-$2.120.19%
LLY · NYSE
Eli Lilly is a pharmaceutical company that develops and sells prescription medicines. Its portfolio includes treatments in obesity and diabetes, oncology, and other disease areas, with recent coverage emphasizing weight-loss medicines, breast-cancer treatment, and research in nervous-system diseases. Customers ultimately include patients, physicians, health systems, insurers, and government payers. The supplied evidence does not provide a segment revenue split, so contributions by therapeutic area cannot be quantified. Lilly generated $65.2 billion of FY2025 revenue and $20.6 billion of net income, up from $45.0 billion and $10.6 billion, respectively, in FY2024.
Eli Lilly shares fell 0.96% over the period, from $1,149.36 to $1,138.28. The stock initially declined to $1,123.91 on September 8, was essentially flat on September 9, slipped to $1,123.00 on September 10, and reached a period low of $1,115.70 on September 11 before rebounding 2.02% on September 14. The supplied evidence does not identify a dated company-specific announcement, earnings release, guidance change, or analyst action that explains the move. Articles discussed obesity-drug data, valuation, pricing, a $2.8 billion deal, and oncology progress, but no timing link to the trading sessions is provided. The week therefore appears to reflect price movement without an evidenced company-specific catalyst; broader market context was not supplied.
Eli Lilly fell 2.84% over the period, from $1,156.73 on August 31 to $1,123.91 on September 8. The stock initially edged higher, reaching $1,160.08 by September 2, before slipping on September 4 and then dropping 2.21% in the final session. Coverage linked the decline to concern around competitor Novartis’ cholesterol-drug setback and noted that Lilly fell more than the broader market, although the supplied evidence does not quantify the market move. Investors also continued weighing the company’s $3.8 billion AtaiBeckley acquisition and its efforts to build growth beyond GLP-1 drugs. No Lilly guidance change or earnings release is identified as a driver of the week.
LLY fell $16.50, or 1.40%, from $1,176.10 to $1,159.60 over the week. The main company-specific catalyst was Lilly’s Aug. 31 announcement that it intends to acquire Merida Biosciences for $2.875 billion, adding the Phase 1 MER511 autoimmune and allergic-disease program and supporting diversification beyond obesity and diabetes. The stock dropped $17.88 on Monday, then recovered only $3.35 across Tuesday and Wednesday before edging lower Thursday. Coverage also highlighted Lilly’s new FDA win for its weight-loss franchise and favorable Zepbound evidence, but those positives did not reverse the Monday decline. No broader market driver is identified in the supplied evidence.
Eli Lilly fell $68.30, or 5.49%, over the week, declining from $1,244.40 to $1,176.10. The stock slipped on Monday and Tuesday, then the decline accelerated Wednesday, when volume increased to 3.01 million shares, before extending lower Thursday on 2.74 million shares. Available coverage does not identify a company-specific event that explains the selloff or a material within-week reversal. The company’s news flow was broadly constructive, including FDA approval for Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes, evidence linking Zepbound use with lower healthcare costs, and a reported deal involving Lilly and BHVN. The shares nevertheless weakened as the market reassessed valuation and the durability of GLP-1-driven growth.
LLY rose $35.40, or 2.93%, from $1,209.00 to $1,244.40 over the week. The advance was concentrated in Tuesday and Wednesday: after a nearly flat Monday close at $1,183.16, the stock gained 3.60% Tuesday and another 4.46% Wednesday on volume of 4.54 million shares. It then gave back $35.94, or 2.81%, Thursday, indicating profit-taking after the sharp midweek rally, before stabilizing Friday. The supplied evidence points to supportive company-specific sentiment around Lilly’s collaboration with Amplitude Therapeutics to develop taRNA vaccines and positive commentary that its GLP-1 portfolio outpaced Novo Nordisk’s in the second quarter. No explicit guidance change or analyst rating action explains Thursday’s reversal.
LLY rose 9.86%, or $110.58, from $1,121.36 on August 3 to $1,231.94 on August 10. The main catalyst was the August 5 earnings release, after which shares jumped 4.86% to $1,169.86 on heavier volume and gained another 1.89% Thursday. Coverage characterized the move as earnings-fueled and linked investor enthusiasm to GLP-1 momentum, including $98 million in second-quarter Foundayo sales and renewed expectations for oral obesity treatment. Shares gave back 0.52% Friday, but resumed the advance with a 3.90% gain on August 10, approaching a record high. Valuation and technical-breakout articles reinforced the positive tone, while insider-selling reports had limited apparent impact.
Eli Lilly fell 8.60%, from $1,220.66 to $1,115.68, declining in every reported session and reaching its lowest close on August 4 as volume rose to 4.10 million shares. The most identifiable company-specific development was the FDA’s Breakthrough Therapy designation for olomorasib in advanced pancreatic cancer, announced Monday, but it did not prevent a 2.4% decline that day. Investors were also positioning ahead of the August 5 earnings release, which was outside the reported trading window. Available evidence does not identify a negative company announcement during the week; the sustained retreat therefore appears driven mainly by pre-earnings positioning and broader reassessment of the stock’s valuation and growth expectations.
